Advertisement

Functional Cortical Neoplasms

  • Ali Zarrinpar
  • Michael W. Yeh
Chapter
Part of the Cancer Treatment and Research book series (CTAR, volume 153)

Abstract

Adrenocortical neoplasms affect men and women equally. While they do not spare children [1], the prevalence of these tumors does increase with age, up to 7% in adults older than 50 [2,3]. Many are found incidentally at autopsy [4] or by imaging done for other purposes. They may be detected because of symptoms or signs related to hormone production [5, 6] or size [5]. Some even appear outside of the actual adrenal gland [7].

Keywords

Cortisol Level Plasma Renin Activity Primary Hyperaldosteronism Adrenal Tumor Laparoscopic Adrenalectomy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Bergada I, Venara M, Maglio S et al (1996) Functional adrenal cortical tumors in pediatric patients: a clinicopathologic and immunohistochemical study of a long term follow-up series. Cancer 77:771–777CrossRefPubMedGoogle Scholar
  2. 2.
    Latronico AC, Chrousos GP (1997) Extensive personal experience: adrenocortical tumors. J Clin Endocrinol Metab 82:1317–1324CrossRefPubMedGoogle Scholar
  3. 3.
    Libe R, Fratticci A, Bertherat J (2007) Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer 14:13–28CrossRefPubMedGoogle Scholar
  4. 4.
    Saeger W, Reinhard K, Reinhard C (1998) Hyperplastic and tumorous lesions of the adrenals in an unselected autopsy series. Endocr Pathol 9:235–239CrossRefPubMedGoogle Scholar
  5. 5.
    Hensen J, Buhl M, Oelkers W (1993) The functional spectrum of adrenocortical adenomas. Med Hypotheses 40:217–222CrossRefPubMedGoogle Scholar
  6. 6.
    Icard P, Goudet P, Charpenay C et al (2001) Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg 25:891–897CrossRefPubMedGoogle Scholar
  7. 7.
    Cassarino DS, Santi M, Arruda A et al (2004) Spinal adrenal cortical adenoma with oncocytic features: report of the first intramedullary case and review of the literature. Int J Surg Pathol 12:259–264CrossRefPubMedGoogle Scholar
  8. 8.
    Henley DJ, van Heerden JA, Grant CS, Carney JA, Carpenter PC (1983) Adrenal cortical carcinoma – a continuing challenge. Surgery 94:926–931PubMedGoogle Scholar
  9. 9.
    Roman S (2006) Adrenocortical carcinoma. Curr Opin Oncol 18:36–42CrossRefPubMedGoogle Scholar
  10. 10.
    Grunberg SM (1982) Development of Cushing’s syndrome and virilization after presentation of a nonfunctioning adrenocortical carcinoma. Cancer 50:815–816CrossRefPubMedGoogle Scholar
  11. 11.
    Weiss LM, Medeiros LJ, Vickery AL Jr (1989) Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol 13:202–206CrossRefPubMedGoogle Scholar
  12. 12.
    van Slooten H, Schaberg A, Smeenk D, Moolenaar AJ (1985) Morphologic characteristics of benign and malignant adrenocortical tumors. Cancer 55:766–773CrossRefPubMedGoogle Scholar
  13. 13.
    Van’t Sant HP, Bouvy ND, Kazemier G et al (2007) The prognostic value of two different histopathological scoring systems for adrenocortical carcinomas. Histopathology 51:239–245Google Scholar
  14. 14.
    Gumbs AA, Gagner M (2006) Laparoscopic adrenalectomy. Best Pract Res Clin Endocrinol Metab 20:483–499CrossRefPubMedGoogle Scholar
  15. 15.
    Ganguly A (1998) Primary aldosteronism. N Engl J Med 339:1828–1834CrossRefPubMedGoogle Scholar
  16. 16.
    White PC (1994) Disorders of aldosterone biosynthesis and action. N Engl J Med 331:250–258CrossRefPubMedGoogle Scholar
  17. 17.
    Auchus RJ (2003) Aldo is back: recent advances and unresolved controversies in hyperaldosteronism. Curr Opin Nephrol Hypertens 12:153–158CrossRefPubMedGoogle Scholar
  18. 18.
    Kaplan NM (2004) The current epidemic of primary aldosteronism: causes and consequences. J Hypertens 22:863–869CrossRefPubMedGoogle Scholar
  19. 19.
    Fogari R, Preti P, Zoppi A, Rinaldi A, Fogari E, Mugellini A (2007) Prevalence of primary aldosteronism among unselected hypertensive patients: a prospective study based on the use of an aldosterone/renin ratio above 25 as a screening test. Hypertens Res 30:111–117CrossRefPubMedGoogle Scholar
  20. 20.
    Mulatero P, Stowasser M, Loh KC et al (2004) Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 89:1045–1050CrossRefPubMedGoogle Scholar
  21. 21.
    Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ (2005) Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 45:1243–1248CrossRefPubMedGoogle Scholar
  22. 22.
    Neville AM, Symington T (1966) Pathology of primary aldosteronism. Cancer 19:1854–1868CrossRefPubMedGoogle Scholar
  23. 23.
    Gleason PE, Weinberger MH, Pratt JH et al (1993) Evaluation of diagnostic tests in the differential diagnosis of primary aldosteronism: unilateral adenoma versus bilateral micronodular hyperplasia. J Urol 150:1365–1368PubMedGoogle Scholar
  24. 24.
    Weinberger MH, Fineberg NS (1993) The diagnosis of primary aldosteronism and separation of two major subtypes. Arch Intern Med 153:2125–2129CrossRefPubMedGoogle Scholar
  25. 25.
    Banks WA, Kastin AJ, Biglieri EG, Ruiz AE (1984) Primary adrenal hyperplasia: a new subset of primary hyperaldosteronism. J Clin Endocrinol Metab 58:783–785CrossRefPubMedGoogle Scholar
  26. 26.
    Imai T, Seo H, Murata Y et al (1991) Dexamethasone-nonsuppressible cortisol in two cases with aldosterone-producing adenoma. J Clin Endocrinol Metab 72:575–581CrossRefPubMedGoogle Scholar
  27. 27.
    Young WF Jr, Hogan MJ, Klee GG, Grant CS, van Heerden JA (1990) Primary aldosteronism: diagnosis and treatment. Mayo Clin Proc 65:96–110PubMedGoogle Scholar
  28. 28.
    Stewart PM (1999) Mineralocorticoid hypertension. Lancet 353:1341–1347CrossRefPubMedGoogle Scholar
  29. 29.
    Zarnegar R, Lee J, Brunaud L et al (2007) Good blood pressure control on antihypertensives, not only response to spironolactone, predicts improved outcome after adrenalectomy for aldosteronoma. Surgery 142:921–929; discussion 9Google Scholar
  30. 30.
    Jackson RV, Lafferty A, Torpy DJ, Stratakis C (2002) New genetic insights in familial hyperaldosteronism. Ann N Y Acad Sci 970:77–88CrossRefPubMedGoogle Scholar
  31. 31.
    Funder JW, Carey RM, Fardella C et al (2008) Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 93:3266–3281CrossRefPubMedGoogle Scholar
  32. 32.
    Doi SA, Abalkhail S, Al-Qudhaiby MM, Al-Humood K, Hafez MF, Al-Shoumer KA (2006) Optimal use and interpretation of the aldosterone renin ratio to detect aldosterone excess in hypertension. J Hum Hypertens 20:482–489CrossRefPubMedGoogle Scholar
  33. 33.
    Kem DC, Weinberger MH, Mayes DM, Nugent CA (1971) Saline suppression of plasma aldosterone in hypertension. Arch Intern Med 128:380–386CrossRefPubMedGoogle Scholar
  34. 34.
    Holland OB, Brown H, Kuhnert L, Fairchild C, Risk M, Gomez-Sanchez CE (1984) Further evaluation of saline infusion for the diagnosis of primary aldosteronism. Hypertension 6:717–723PubMedGoogle Scholar
  35. 35.
    Gandour MJ, Grizzle WE (1986) A small adrenocortical carcinoma with aggressive behavior. An evaluation of criteria for malignancy. Arch Pathol Lab Med 110:1076–9Google Scholar
  36. 36.
    Cohen RJ, Brits R, Phillips JI, Botha JR (1991) Primary hyperaldosteronism due to a functional black (pigmented) adenoma of the adrenal cortex. Arch Pathol Lab Med 115:813–815PubMedGoogle Scholar
  37. 37.
    Bugg MF, Ribeiro RC, Roberson PK et al (1994) Correlation of pathologic features with clinical outcome in pediatric adrenocortical neoplasia. A study of a Brazilian population. Brazilian Group for Treatment of Childhood Adrenocortical Tumors. Am J Clin Pathol 101:625–629Google Scholar
  38. 38.
    Evans HL, Vassilopoulou-Sellin R (1996) Adrenal cortical neoplasms. A study of 56 cases. Am J Clin Pathol 105:76–86Google Scholar
  39. 39.
    Vyberg M, Sestoft L (1986) Combined adrenal myelolipoma and adenoma associated with Cushing’s syndrome. Am J Clin Pathol 86:541–545PubMedGoogle Scholar
  40. 40.
    Sienkowski IK, Watkins RM, Anderson VE (1984) Primary tumorous aldosteronism due to a black adrenal adenoma: a light and electron microscopic study. J Clin Pathol 37:143–149CrossRefPubMedGoogle Scholar
  41. 41.
    Komiya I, Takasu N, Aizawa T et al (1985) Black (or brown) adrenal cortical adenoma: its characteristic features on computed tomography and endocrine data. J Clin Endocrinol Metab 61:711–717CrossRefPubMedGoogle Scholar
  42. 42.
    Macadam RF (1971) Black adenoma of the human adrenal cortex. Cancer 27:116–119CrossRefPubMedGoogle Scholar
  43. 43.
    Damron TA, Schelper RL, Sorensen L (1987) Cytochemical demonstration of neuromelanin in black pigmented adrenal nodules. Am J Clin Pathol 87:334–341PubMedGoogle Scholar
  44. 44.
    Ivsic T, Komorowski RA, Sudakoff GS, Wilson SD, Datta MW (2002) Adrenal cortical adenoma with adrenalin-type neurosecretory granules clinically mimicking a pheochromocytoma. Arch Pathol Lab Med 126:1530–1533PubMedGoogle Scholar
  45. 45.
    Hoang MP, Ayala AG, Albores-Saavedra J (2002) Oncocytic adrenocortical carcinoma: a morphologic, immunohistochemical and ultrastructural study of four cases. Mod Pathol 15:973–978CrossRefPubMedGoogle Scholar
  46. 46.
    Lin BT, Bonsib SM, Mierau GW, Weiss LM, Medeiros LJ (1998) Oncocytic adrenocortical neoplasms: a report of seven cases and review of the literature. Am J Surg Pathol 22:603–614CrossRefPubMedGoogle Scholar
  47. 47.
    Brown FM, Gaffey TA, Wold LE, Lloyd RV (2000) Myxoid neoplasms of the adrenal cortex: a rare histologic variant. Am J Surg Pathol 24:396–401CrossRefPubMedGoogle Scholar
  48. 48.
    Feldberg E, Guy M, Eisenkraft S, Czernobilsky B (1996) Adrenal cortical adenoma with extensive fat cell metaplasia. Pathol Res Pract 192:62–65; discussion 6Google Scholar
  49. 49.
    Trojan J, Schwarz W, Sarrazin C, Thalhammer A, Vogl TJ, Dietrich CF (2002) Role of ultrasonography in the detection of small adrenal masses. Ultraschall Med 23:96–100CrossRefPubMedGoogle Scholar
  50. 50.
    McClennan BL (1991) Oncologic imaging. Staging and follow-up of renal and adrenal carcinoma. Cancer 67:1199–208Google Scholar
  51. 51.
    Doppman JL, Gill JR Jr, Miller DL et al (1992) Distinction between hyperaldosteronism due to bilateral hyperplasia and unilateral aldosteronoma: reliability of CT. Radiology 184:677–682PubMedGoogle Scholar
  52. 52.
    Mayo-Smith WW, Boland GW, Noto RB, Lee MJ (2001) State-of-the-art adrenal imaging. Radiographics 21:995–1012PubMedGoogle Scholar
  53. 53.
    Szolar DH, Korobkin M, Reittner P et al (2005) Adrenocortical carcinomas and adrenal pheochromocytomas: mass and enhancement loss evaluation at delayed contrast-enhanced CT. Radiology 234:479–485CrossRefPubMedGoogle Scholar
  54. 54.
    Ilias I, Sahdev A, Reznek RH, Grossman AB, Pacak K (2007) The optimal imaging of adrenal tumours: a comparison of different methods. Endocr Relat Cancer 14:587–599CrossRefPubMedGoogle Scholar
  55. 55.
    Daunt N (2005) Adrenal vein sampling: how to make it quick, easy, and successful. Radiographics 25(Suppl 1):S143–S158CrossRefPubMedGoogle Scholar
  56. 56.
    Espiner EA, Ross DG, Yandle TG, Richards AM, Hunt PJ (2003) Predicting surgically remedial primary aldosteronism: role of adrenal scanning, posture testing, and adrenal vein sampling. J Clin Endocrinol Metab 88:3637–3644CrossRefPubMedGoogle Scholar
  57. 57.
    Young WF, Stanson AW, Thompson GB, Grant CS, Farley DR, van Heerden JA (2004) Role for adrenal venous sampling in primary aldosteronism. Surgery 136:1227–1235CrossRefPubMedGoogle Scholar
  58. 58.
    Tan YY, Ogilvie JB, Triponez F et al (2006) Selective use of adrenal venous sampling in the lateralization of aldosterone-producing adenomas. World J Surg 30:879–885; discussion 86–87Google Scholar
  59. 59.
    Harvey A, Kline G, Pasieka JL (2006) Adrenal venous sampling in primary hyperaldosteronism: comparison of radiographic with biochemical success and the clinical decision-making with “less than ideal” testing. Surgery 140:847–853; discussion 53–55Google Scholar
  60. 60.
    Lal G, Duh QY (2003) Laparoscopic adrenalectomy – indications and technique. Surg Oncol 12:105–123CrossRefPubMedGoogle Scholar
  61. 61.
    Mohler JL, Flueck JA, McRoberts JW (1986) Adrenal insufficiency following unilateral adrenalectomy: a case report. J Urol 135:554–556PubMedGoogle Scholar
  62. 62.
    Nagai Y, Ohsawa K, Hayakawa T et al (1994) Acute adrenal insufficiency after unilateral adrenalectomy in Cushing’s syndrome: precipitation by lithium-induced thyrotoxicosis during cortisol replacement. Endocr J 41:177–182CrossRefPubMedGoogle Scholar
  63. 63.
    Kazama I, Komatsu Y, Ohiwa T, Sanayama K, Nagata M (2005) Delayed adrenal insufficiency long after unilateral adrenalectomy: prolonged glucocorticoid therapy reduced reserved secretory capacity of cortisol. Int J Urol 12:574–577CrossRefPubMedGoogle Scholar
  64. 64.
    Orth DN (1995) Cushing’s syndrome. N Engl J Med 332:791–803CrossRefPubMedGoogle Scholar
  65. 65.
    Lindholm J, Juul S, Jorgensen JO et al (2001) Incidence and late prognosis of cushing’s syndrome: a population-based study. J Clin Endocrinol Metab 86:117–123CrossRefPubMedGoogle Scholar
  66. 66.
    Perry RR, Nieman LK, Cutler GB Jr et al (1989) Primary adrenal causes of Cushing’s syndrome. Diagnosis and surgical management. Ann Surg 210:59–68CrossRefPubMedGoogle Scholar
  67. 67.
    Raff H, Findling JW (2003) A physiologic approach to diagnosis of the Cushing syndrome. Ann Intern Med 138:980–991PubMedGoogle Scholar
  68. 68.
    Aiba M, Hirayama A, Iri H et al (1991) Adrenocorticotropic hormone-independent bilateral adrenocortical macronodular hyperplasia as a distinct subtype of Cushing’s syndrome. Enzyme histochemical and ultrastructural study of four cases with a review of the literature. Am J Clin Pathol 96:334–340PubMedGoogle Scholar
  69. 69.
    Joffe SN, Brown C (1983) Nodular adrenal hyperplasia and Cushing’s syndrome. Surgery 94:919–925PubMedGoogle Scholar
  70. 70.
    Smals AG, Pieters GF, van Haelst UJ, Kloppenborg PW (1984) Macronodular adrenocortical hyperplasia in long-standing Cushing’s disease. J Clin Endocrinol Metab 58:25–31CrossRefPubMedGoogle Scholar
  71. 71.
    Zeiger MA, Nieman LK, Cutler GB et al (1991) Primary bilateral adrenocortical causes of Cushing’s syndrome. Surgery 110:1106–1115PubMedGoogle Scholar
  72. 72.
    Young WF Jr, Carney JA, Musa BU, Wulffraat NM, Lens JW, Drexhage HA (1989) Familial Cushing’s syndrome due to primary pigmented nodular adrenocortical disease. Reinvestigation 50 years later. N Engl J Med 321:1659–1664Google Scholar
  73. 73.
    Aiba M, Kawakami M, Ito Y, Fujimoto Y, Suda T, Demura H (1992) Bilateral adrenocortical adenomas causing Cushing’s syndrome. Report of two cases with enzyme histochemical and ultrastructural studies and a review of the literature. Arch Pathol Lab Med 116:146–150PubMedGoogle Scholar
  74. 74.
    Newell-Price J, Bertagna X, Grossman AB, Nieman LK (2006) Cushing’s syndrome. Lancet 367:1605–1617CrossRefPubMedGoogle Scholar
  75. 75.
    Gilbert MG, Cleveland WW (1970) Cushing’s syndrome in infancy. Pediatrics 46:217–229PubMedGoogle Scholar
  76. 76.
    Neville AM, Symington T (1972) Bilateral adrenocortical hyperplasia in children with Cushing’s syndrome. J Pathol 107:95–106CrossRefPubMedGoogle Scholar
  77. 77.
    Thomas CG Jr, Smith AT, Griffith JM, Askin FB (1984) Hyperadrenalism in childhood and adolescence. Ann Surg 199:538–548CrossRefPubMedGoogle Scholar
  78. 78.
    Hartmann CA, Gross U, Stein H (1992) Cushing syndrome-associated pheochromocytoma and adrenal carcinoma. An immunohistological investigation. Pathol Res Pract 188:287–295PubMedGoogle Scholar
  79. 79.
    Nieman LK, Biller BM, Findling JW et al (2008) The diagnosis of Cushing’s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 93:1526–1540CrossRefPubMedGoogle Scholar
  80. 80.
    Papanicolaou DA, Mullen N, Kyrou I, Nieman LK (2002) Nighttime salivary cortisol: a useful test for the diagnosis of Cushing’s syndrome. J Clin Endocrinol Metab 87:4515–4521CrossRefPubMedGoogle Scholar
  81. 81.
    Putignano P, Dubini A, Toja P et al (2001) Salivary cortisol measurement in normal-weight, obese and anorexic women: comparison with plasma cortisol. Eur J Endocrinol 145:165–171CrossRefPubMedGoogle Scholar
  82. 82.
    Rockall AG, Babar SA, Sohaib SA et al (2004) CT and MR imaging of the adrenal glands in ACTH-independent cushing syndrome. Radiographics 24:435–452CrossRefPubMedGoogle Scholar
  83. 83.
    Tsuiki M, Tanabe A, Takagi S, Naruse M, Takano K (2008) Cardiovascular risks and their long-term clinical outcome in patients with subclinical Cushing’s syndrome. Endocr J 55:737–745CrossRefPubMedGoogle Scholar
  84. 84.
    Tauchmanova L, Rossi R, Biondi B et al (2002) Patients with subclinical Cushing’s syndrome due to adrenal adenoma have increased cardiovascular risk. J Clin Endocrinol Metab 87:4872–4878CrossRefPubMedGoogle Scholar
  85. 85.
    Mitchell IC, Auchus RJ, Juneja K et al (2007) “Subclinical Cushing’s syndrome” is not subclinical: improvement after adrenalectomy in 9 patients. Surgery 142:900–905; discussion 5 e1Google Scholar
  86. 86.
    Esposito F, Dusick JR, Cohan P et al (2006) Clinical review: early morning cortisol levels as a predictor of remission after transsphenoidal surgery for Cushing’s disease. J Clin Endocrinol Metab 91:7–13CrossRefPubMedGoogle Scholar
  87. 87.
    Ciftci AO, Senocak ME, Tanyel FC, Buyukpamukcu N (2001) Adrenocortical tumors in children. J Pediatr Surg 36:549–554CrossRefPubMedGoogle Scholar
  88. 88.
    Sakai Y, Yanase T, Hara T, Takayanagi R, Haji M, Nawata H (1994) Mechanism of abnormal production of adrenal androgens in patients with adrenocortical adenomas and carcinomas. J Clin Endocrinol Metab 78:36–40CrossRefPubMedGoogle Scholar
  89. 89.
    Heinbecker P, O’Neal LW, Ackerman LV (1957) Functioning and nonfunctioning adrenal cortical tumors. Surg Gynecol Obstet 105:21–33PubMedGoogle Scholar
  90. 90.
    D’Alva C, Abiven-Lepage G, Viallon V et al (2008) Sex steroids in androgen-secreting adrenocortical tumors: clinical and hormonal features in comparison with non tumoral causes of androgen excess. Eur J Endocrinol 159(5):641–647Google Scholar
  91. 91.
    Del Gaudio AD, Del Gaudio GA (1993) Virilizing adrenocortical tumors in adult women. Report of 10 patients, 2 of whom each had a tumor secreting only testosterone. Cancer 72:1997–2003Google Scholar
  92. 92.
    Fischler DF, Nunez C, Levin HS, McMahon JT, Sheeler LR, Adelstein DJ (1992) Adrenal carcinosarcoma presenting in a woman with clinical signs of virilization. A case report with immunohistochemical and ultrastructural findings. Am J Surg Pathol 16:626–631Google Scholar
  93. 93.
    Gabrilove JL, Sharma DC, Wotiz HH, Dorfman RI (1965) Feminizing adrenocortical tumors in the male. A review of 52 cases including a case report. medicine (Baltimore) 44:37–79Google Scholar
  94. 94.
    Burrington JD, Stephens CA (1969) Virilizing tumors of the adrenal gland in childhood: report of eight cases. J Pediatr Surg 4:291–302CrossRefPubMedGoogle Scholar
  95. 95.
    Kenny FM, Hashida Y, Askari HA, Sieber WH, Fetterman GH (1968) Virilizing tumors of the adrenal cortex. Am J Dis Child 115:445–458PubMedGoogle Scholar
  96. 96.
    Loszio FA, Toth S, Kocsis J, Pavo SM (2001) Testosterone-secreting gonadotropin-responsive adrenal adenoma and its treatment with the antiandrogen flutamide. J Endocrinol Invest 24:622–627PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.David Geffen School of MedicineUniversity of CaliforniaLos AngelesUSA

Personalised recommendations